Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 4.8% - What's Next?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) dropped 4.8% on Tuesday . The stock traded as low as $15.06 and last traded at $14.76. Approximately 63,820 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 1,262,963 shares. The stock had previously closed at $15.50.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ARWR shares. Royal Bank of Canada restated an "outperform" rating and issued a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. HC Wainwright reiterated a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a "sell" rating in a research note on Friday, December 20th. B. Riley restated a "buy" rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Finally, Sanford C. Bernstein dropped their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating for the company in a research report on Friday, November 29th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of "Hold" and an average price target of $41.44.

Remove Ads

Arrowhead Pharmaceuticals Stock Performance

The company has a market cap of $1.90 billion, a PE ratio of -2.67 and a beta of 0.92. The business has a fifty day simple moving average of $18.13 and a two-hundred day simple moving average of $19.62. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). Research analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, COO Patrick O'brien sold 29,184 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $19.82, for a total value of $578,426.88. Following the completion of the sale, the chief operating officer now directly owns 535,201 shares of the company's stock, valued at $10,607,683.82. This represents a 5.17 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher Richard Anzalone sold 11,520 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $19.05, for a total value of $219,456.00. Following the completion of the transaction, the chief executive officer now owns 3,764,252 shares in the company, valued at $71,709,000.60. This trade represents a 0.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 286,317 shares of company stock worth $5,049,735 in the last three months. 4.30% of the stock is owned by corporate insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Mackenzie Financial Corp purchased a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $137,000. GF Fund Management CO. LTD. bought a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $49,000. Neo Ivy Capital Management acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth approximately $318,000. Two Sigma Advisers LP raised its stake in shares of Arrowhead Pharmaceuticals by 330.7% in the 4th quarter. Two Sigma Advisers LP now owns 430,700 shares of the biotechnology company's stock worth $8,097,000 after buying an additional 330,700 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of Arrowhead Pharmaceuticals by 281.3% during the 4th quarter. Two Sigma Investments LP now owns 794,373 shares of the biotechnology company's stock valued at $14,934,000 after acquiring an additional 586,062 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.